{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:57:33Z","timestamp":1793890653664,"version":"4.8.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Postpartum hemorrhage (PPH) is the leading cause of global maternal mortality and accounts for approximately one-quarter of all maternal deaths worldwide. Prevention of excess maternal deaths requires a coordinated approach to prevention, early recognition, and intervention by a multidisciplinary team. Although some women have risk factors for PPH that can be identified during pregnancy or during labor or birth, most women with severe PPH do not have any risk factors. Therefore, all pregnant women must be considered to be at risk of PPH. Common causes include uterine atony, retained placenta, trauma to the genital tract or uterus, and coagulopathy. The pivotal role of fibrinogen and hyperfibrinolysis in the evolution and as a treatment target for PPH is increasingly recognized. Coagulopathy can be an early feature in PPH that may be unrecognized, as it can be present before massive transfusion has occurred. Identification of coagulopathy by viscoelastic point-of-care testing or conventional laboratory assays can be helpful in guiding management of PPH and preventing severe maternal outcomes.<\/jats:p>","DOI":"10.1182\/hematology.2020000139","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T22:33:06Z","timestamp":1607121186000},"page":"542-546","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management"],"prefix":"10.1182","volume":"2020","author":[{"given":"Claire","family":"McLintock","sequence":"first","affiliation":[{"name":"National Women\u2019s Health, Auckland City Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020121621260713900_B1","unstructured":"World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva, Switzerland: WHO; 2012."},{"issue":"7","key":"2020121621260713900_B2","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/trf.12550","article-title":"Evaluation and management of postpartum hemorrhage: consensus from an international expert panel","volume":"54","author":"Abdul-Kadir","year":"2014","journal-title":"Transfusion"},{"issue":"5","key":"2020121621260713900_B3","doi-asserted-by":"crossref","first-page":"449.e1","DOI":"10.1016\/j.ajog.2013.07.007","article-title":"Incidence, risk factors, and temporal trends in severe postpartum hemorrhage","volume":"209","author":"Kramer","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"2020121621260713900_B4","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/j.1538-7836.2011.04398.x","article-title":"Obstetric hemorrhage","volume":"9","author":"McLintock","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2020121621260713900_B5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1471-0528.2006.01018.x","article-title":"Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions","volume":"113","author":"Bose","year":"2006","journal-title":"BJOG"},{"issue":"5","key":"2020121621260713900_B6","doi-asserted-by":"crossref","first-page":"e0217864","DOI":"10.1371\/journal.pone.0217864","article-title":"Early warning systems in obstetrics: A systematic literature review","volume":"14","author":"Umar","year":"2019","journal-title":"PLoS One"},{"key":"2020121621260713900_B7","unstructured":"Health Quality and Safety Commission New Zealand. The New Zealand national maternity early warning system (MEWS) maternity vital signs chart user guide. Wellington, New Zealand: HQSC; 19 June 2020. http:\/\/www.hqsc.govt.nz\/mews. Accessed 11 October 2020."},{"issue":"11","key":"2020121621260713900_B8","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1111\/jth.13126","article-title":"A critical appraisal of point-of-care coagulation testing in critically ill patients","volume":"13","author":"Levi","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2020121621260713900_B9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1538-7836.2007.02297.x","article-title":"The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage","volume":"5","author":"Charbit","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2020121621260713900_B10","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/bja\/aes096","article-title":"Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial","volume":"108","author":"Cortet","year":"2012","journal-title":"Br J Anaesth"},{"issue":"11","key":"2020121621260713900_B11","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1182\/blood-2014-04-567891","article-title":"Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020121621260713900_B12","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/bja\/aeu444","article-title":"Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial","volume":"114","author":"Wikkels\u00f8","year":"2015","journal-title":"Br J Anaesth"},{"issue":"3","key":"2020121621260713900_B13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/bja\/aex181","article-title":"Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double blind randomised controlled trial","volume":"119","author":"Collins","year":"2017","journal-title":"Br J Anaesth"},{"issue":"2","key":"2020121621260713900_B14","doi-asserted-by":"crossref","first-page":"e000854","DOI":"10.1136\/bmjoq-2019-000854","article-title":"Designing and implementing an all Wales postpartum haemorrhage quality improvement project: OBS Cymru (the Obstetric Bleeding Strategy for Wales)","volume":"9","author":"Bell","year":"2020","journal-title":"BMJ Open Qual"},{"key":"2020121621260713900_B15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijoa.2018.08.008","article-title":"Management of postpartum haemorrhage: from research into practice, a narrative review of the literature and the Cardiff experience","volume":"37","author":"Collins","year":"2019","journal-title":"Int J Obstet Anesth"},{"issue":"1","key":"2020121621260713900_B16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jth.13174","article-title":"Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH","volume":"14","author":"Collins","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"9734","key":"2020121621260713900_B17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"Shakur","year":"2010","journal-title":"Lancet"},{"issue":"10084","key":"2020121621260713900_B18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(17)30638-4","article-title":"Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial [published correction appears in Lancet. 2017;389(10084):2104]","volume":"389","author":"WOMAN Trial Collaborators","year":"2017","journal-title":"Lancet"},{"key":"2020121621260713900_B19","unstructured":"World Health Organization. WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage. Geneva, Switzerland: WHO; 31 October 2017. Available at https:\/\/extranet.who.int\/rhl\/topics\/preconception-pregnancy-childbirth-and-postpartum-care\/postpartum-care\/who-recommendation-tranexamic-acid-treatment-postpartum-haemorrhage. Accessed 9 September 2020."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/542\/1794951\/hem2020000139c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/542\/1794951\/hem2020000139c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T13:15:01Z","timestamp":1608297301000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/542\/474319\/Prevention-and-treatment-of-postpartum-hemorrhage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000139","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}